Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033

Table of Contents

1 Markets

• 1.1 Product Definition
  • 1.1.1 Inclusion Criteria for the Report
  • 1.1.2 Exclusion Criteria for the Report
• 1.2 Market Scope
  • 1.2.1 Scope of the Work
  • 1.2.2 Key Questions Answered in the Report
• 1.3 Research Methodology
  • 1.3.1 Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Research Methodology
  • 1.3.2 Data Sources
    • 1.3.2.1 Primary Data Sources
    • 1.3.2.2 Secondary Data Sources
  • 1.3.3 Market Estimation Model
    • 1.3.3.1 Criteria for Company Profiling
• 1.4 Market Overview
  • 1.4.1 Global Market Scenario
    • 1.4.1.1 Realistic Growth Scenario
    • 1.4.1.2 Optimistic Scenario
      • 1.4.1.2.1 Pessimistic Scenario
  • 1.4.2 Market Footprint and Growth Potential
  • 1.4.3 COVID-19 Impact on Market
    • 1.4.3.1 Impact on Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
      • 1.4.3.1.1 COVID-19 Impact: Current Scenario of the Market
      • 1.4.3.1.2 Pre- and Post-COVID-19 Impact Assessment
        • 1.4.3.1.2.1 Pre-COVID-19 Phase
        • 1.4.3.1.2.2 Post-COVID-19 Phase
  • 1.4.4 Unmet Needs
    • 1.4.4.1 Addressing Unmet Needs in the AAV Manufacturing Process
      • 1.4.4.1.1 Upstream Processing
      • 1.4.4.1.2 Downstream Processing

2 Industry Analysis

• 2.1 Overview
• 2.2 Regulatory Guidance
  • 2.2.1 Current Good Manufacturing Practice (CGMP) Regulations
    • 2.2.1.1 U.S.
    • 2.2.1.2 Europe
• 2.3 Quality Aspects of Cell and Gene Therapy by the European Medicines Agency (EMA)
  • 2.3.1 Vector Design
  • 2.3.2 Development Genetics
  • 2.3.3 Drug Substance
    • 2.3.3.1 Manufacture
    • 2.3.3.2 Description of Manufacturing Process and Process Controls
  • 2.3.4 Starting Materials
  • 2.3.5 Characterization
  • 2.3.6 Drug Product
    • 2.3.6.1 Manufacturing of the Drug Product and Process Controls
• 2.4 U.S. Food and Drug Administration (FDA) Requirements for Viral Vectors
  • 2.4.1 Clinical Safety Evaluations for AAV Vectors

3 Market Dynamics

• 3.1 Overview
• 3.2 Impact Analysis
• 3.3 Market Drivers
  • 3.3.1 Rise in Preclinical and Clinical Activities around Viral-Vector-Based Gene Therapies Propelling the Demand for CDMOs in the Market
  • 3.3.2 Increasing Number of Emerging Players in the Cell and Gene Therapy (CGT) Sector Driving the Demand for CDMO Services
  • 3.3.3 High Investment of CDMOs in Advancing Viral-Vector Manufacturing and Research in Gene Therapies
• 3.4 Market Restraints
  • 3.4.1 Limitations in the Development of Analytical Methods for Large-Scale Adeno-Associated Virus (AAV) Biomanufacturing
  • 3.4.2 High Cost of Viral-Vector Manufacturing Creating a Challenge for Emerging CDMO Players in the Market
• 3.5 Market Opportunities
  • 3.5.1 Development in the Advancements of AAV Biomanufacturing Facilities by Strategic Collaborations of CDMO Service Provider Companies

4 Competitive Landscape

• 4.1 Overview
• 4.2 Key Strategies and Developments
  • 4.2.1 Synergistic Activities
  • 4.2.2 Product Launches
  • 4.2.3 Acquisitions and Mergers
  • 4.2.4 Product Approvals
  • 4.2.5 Business Expansions, Funding, and Investments
• 4.3 Market Share Analysis
• 4.4 Growth-Share Analysis
  • 4.4.1 By Phase of Development
• 4.5 Supply Chain Analysis
  • 4.5.1 Key Entities in Supply Chain

5 By Phase of Development

• 5.1 Overview
• 5.2 Clinical Phase I
• 5.3 Clinical Phase II
• 5.4 Clinical Phase III
• 5.5 Commercial Phase

6 By Workflow

• 6.1 Overview
• 6.2 Upstream Processing
• 6.3 Downstream Processing
• 6.4 Formulation and Fill and Finish

7 By Indication

• 7.1 Overview
• 7.2 Oncology
• 7.3 Ophthalmology
• 7.4 Infectious Disease
• 7.5 Metabolic Disorder
• 7.6 Neurological Disorder
• 7.7 Other

8 By Culture Type

• 8.1 Overview
• 8.2 Adherent Culture
• 8.3 Suspension Culture

9 By Region

• 9.1 Overview
  • 9.1.1 North America
    • 9.1.1.1 North America Market Size and Forecast
      • 9.1.1.1.1 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.1.1.2 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.1.1.3 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.1.1.4 North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.1.2 U.S.
      • 9.1.1.2.1 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.1.2.2 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.1.2.3 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.1.2.4 U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.1.3 Canada
      • 9.1.1.3.1 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.1.3.2 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.1.3.3 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.1.3.4 Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
  • 9.1.2 Europe
    • 9.1.2.1 Europe Market Size and Forecast
      • 9.1.2.1.1 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.2.1.2 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.2.1.3 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.2.1.4 Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.2.2 U.K.
      • 9.1.2.2.1 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.2.2.2 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.2.2.3 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.2.2.4 U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.2.3 Germany
      • 9.1.2.3.1 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.2.3.2 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.2.3.3 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.2.3.4 Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.2.4 France
      • 9.1.2.4.1 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.2.4.2 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.2.4.3 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.2.4.4 France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.2.5 Italy
      • 9.1.2.5.1 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.2.5.2 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.2.5.3 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.2.5.4 Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.2.6 Spain
      • 9.1.2.6.1 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.2.6.2 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.2.6.3 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.2.6.4 Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.2.7 Rest-of-Europe
      • 9.1.2.7.1 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.2.7.2 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.2.7.3 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.2.7.4 Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
  • 9.1.3 Asia-Pacific
    • 9.1.3.1 Asia-Pacific Market Size and Forecast
      • 9.1.3.1.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.3.1.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.3.1.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.3.1.4 Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.3.2 China
      • 9.1.3.2.1 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.3.2.2 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.3.2.3 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.3.2.4 China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.3.3 Japan
      • 9.1.3.3.1 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.3.3.2 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.3.3.3 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.3.3.4 Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.3.4 India
      • 9.1.3.4.1 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.3.4.2 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.3.4.3 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.3.4.4 India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.3.5 Australia
      • 9.1.3.5.1 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.3.5.2 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.3.5.3 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.3.5.4 Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.3.6 South Korea
      • 9.1.3.6.1 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.3.6.2 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.3.6.3 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.3.6.4 South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.3.7 Rest-of-Asia-Pacific
      • 9.1.3.7.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.3.7.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.3.7.3 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.3.7.4 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
  • 9.1.4 Latin America
    • 9.1.4.1 Latin America Market Size and Forecast
      • 9.1.4.1.1 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.4.1.2 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.4.1.3 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.4.1.4 Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.4.2 Brazil
      • 9.1.4.2.1 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.4.2.2 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.4.2.3 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.4.2.4 Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.4.3 Mexico
      • 9.1.4.3.1 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.4.3.2 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.4.3.3 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.4.3.4 Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.4.4 Rest-of-Latin America
      • 9.1.4.4.1 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.4.4.2 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.4.4.3 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.4.4.4 Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
  • 9.1.5 Middle East and Africa
    • 9.1.5.1 Middle East and Africa Market Size and Forecast
      • 9.1.5.1.1 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.5.1.2 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.5.1.3 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.5.1.4 Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.5.2 K.S.A.
      • 9.1.5.2.1 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.5.2.2 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.5.2.3 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.5.2.4 K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.5.3 U.A.E.
      • 9.1.5.3.1 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.5.3.2 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.5.3.3 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.5.3.4 U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.5.4 Israel
      • 9.1.5.4.1 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.5.4.2 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.5.4.3 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.5.4.4 Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.5.5 Turkiye
      • 9.1.5.5.1 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.5.5.2 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.5.5.3 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.5.5.4 Turkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.5.6 South Africa
      • 9.1.5.6.1 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.5.6.2 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.5.6.3 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.5.6.4 South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
    • 9.1.5.7 Rest-of-Middle East and Africa
      • 9.1.5.7.1 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
      • 9.1.5.7.2 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
      • 9.1.5.7.3 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
      • 9.1.5.7.4 Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)

10 Company Profiles

• 10.1 Overview
• 10.2 Cell and Gene Therapy Biomanufacturing CDMO - Focused on AAV Ecosystem Active Players
• 10.3 Company Profiles
  • 10.3.1 AGC Biologics.
    • 10.3.1.1 Company Overview
    • 10.3.1.2 Role of AGC Biologics. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.1.3 Key Competitors
    • 10.3.1.4 Financials
    • 10.3.1.5 Corporate Strategies
      • 10.3.1.5.1 Synergistic Activities
      • 10.3.1.5.2 Business Expansions, Funding, and Investments
    • 10.3.1.6 Business Strategies
      • 10.3.1.6.1 Product Launch
    • 10.3.1.7 Analyst Perspective
  • 10.3.2 Charles River Laboratories International, Inc.
    • 10.3.2.1 Company Overview
    • 10.3.2.2 Role of Charles River Laboratories International, Inc. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.2.3 Key Competitors
    • 10.3.2.4 Financials
    • 10.3.2.5 Corporate Strategies
      • 10.3.2.5.1 Synergistic Activities
      • 10.3.2.5.2 Business Expansions
    • 10.3.2.6 Business Strategies
      • 10.3.2.6.1 Product Launches
    • 10.3.2.7 Analyst Perspective
  • 10.3.3 Catalent, Inc.
    • 10.3.3.1 Company Overview
    • 10.3.3.2 Role of Catalent, Inc. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.3.3 Key Competitors
    • 10.3.3.4 Financials
    • 10.3.3.5 Corporate Strategies
      • 10.3.3.5.1 Synergistic Activities
      • 10.3.3.5.2 Business Expansions
    • 10.3.3.6 Business Strategies
      • 10.3.3.6.1 Product Launches/ Approvals
    • 10.3.3.7 Analyst Perspective
  • 10.3.4 Creative Biogene
    • 10.3.4.1 Company Overview
    • 10.3.4.2 Role of Creative Biogene in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.4.3 Analyst Perspective
  • 10.3.5 Danaher. (Cytiva)
    • 10.3.5.1 Company Overview
    • 10.3.5.2 Role of Danaher. (Cytiva) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.5.3 Key Competitors
    • 10.3.5.4 Financials
    • 10.3.5.5 Key Insights about the Financial Health of the Company
    • 10.3.5.6 Corporate Strategies
      • 10.3.5.6.1 Mergers and Acquisitions
      • 10.3.5.6.2 Synergistic Activities
      • 10.3.5.6.3 Business Expansions
    • 10.3.5.7 Business Strategies
      • 10.3.5.7.1 Product Launches
    • 10.3.5.8 Analyst Perspective
  • 10.3.6 FUJIFILM Diosynth Biotechnologies
    • 10.3.6.1 Company Overview
    • 10.3.6.2 Role of FUJIFILM Diosynth Biotechnologies in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.6.3 Key Competitors
    • 10.3.6.4 Corporate Strategies
      • 10.3.6.4.1 Synergistic Activities
        • 10.3.6.4.1.1 Business Expansions
    • 10.3.6.5 Analyst Perspective
  • 10.3.7 Genscript Biotech Corporation (GenScript ProBio)
    • 10.3.7.1 Company Overview
    • 10.3.7.2 Role of Genscript Biotech Corporation (GenScript ProBio) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.7.3 Key Competitors
    • 10.3.7.4 Financials
    • 10.3.7.5 Key Insights about the Financial Health of the Company
    • 10.3.7.6 Analyst Perspective
  • 10.3.8 Lonza.
    • 10.3.8.1 Company Overview
    • 10.3.8.2 Role of Lonza. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.8.3 Key Competitors
    • 10.3.8.4 Financials
    • 10.3.8.5 Business Strategies
      • 10.3.8.5.1 Product Launch
    • 10.3.8.6 Analyst Perspective
  • 10.3.9 Merck KGaA
    • 10.3.9.1 Company Overview
    • 10.3.9.2 Role of Merck KGaA in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.9.3 Key Competitors
    • 10.3.9.4 Financials
    • 10.3.9.5 Business Strategies
      • 10.3.9.5.1 Product Launch
    • 10.3.9.6 Analyst Perspective
  • 10.3.10 Porton Advanced Solution Ltd.
    • 10.3.10.1 Company Overview
    • 10.3.10.2 Role of Porton Advanced Solution Ltd. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.10.3 Key Competitors
    • 10.3.10.4 Corporate Strategies
      • 10.3.10.4.1 Synergistic Activities
    • 10.3.10.5 Analyst Perspective
  • 10.3.11 PackGene Biotech
    • 10.3.11.1 Company Overview
    • 10.3.11.2 Role of PackGene Biotech in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.11.3 Key Competitors
    • 10.3.11.4 Analyst Perspective
  • 10.3.12 Oxford Biomedica plc
    • 10.3.12.1 Company Overview
    • 10.3.12.2 Role of Oxford Biomedica plc in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.12.3 Key Competitors
    • 10.3.12.4 Financials
    • 10.3.12.5 Corporate Strategies
      • 10.3.12.5.1 Synergistic Activities
      • 10.3.12.5.2 Business Expansions
    • 10.3.12.6 Analyst Perspective
  • 10.3.13 Thermo Fisher Scientific Inc. (Patheon Pharma Services)
    • 10.3.13.1 Company Overview
    • 10.3.13.2 Role of Thermo Fisher Scientific Inc. (Patheon Pharma Services) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.13.3 Key Competitors
    • 10.3.13.4 Financials
    • 10.3.13.5 Key Insights about the Financial Health of the Company
    • 10.3.13.6 Corporate Strategies
      • 10.3.13.6.1 Mergers and Acquisitions
      • 10.3.13.6.2 Business Expansions
    • 10.3.13.7 Business Strategies
      • 10.3.13.7.1 Product Launches
    • 10.3.13.8 Analyst Perspective
  • 10.3.14 WuXi AppTec
    • 10.3.14.1 Company Overview
    • 10.3.14.2 Role of WuXi AppTec in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
    • 10.3.14.3 Key Competitors
    • 10.3.14.4 Financials
    • 10.3.14.5 Corporate Strategies
      • 10.3.14.5.1 Mergers and Acquisitions
      • 10.3.14.5.2 Synergistic Activities
    • 10.3.14.6 Business Strategies
      • 10.3.14.6.1 Product Launches
    • 10.3.14.7 Analyst Perspective
  • 10.3.15 Emerging Companies
    • 10.3.15.1 Asklepios BioPharmaceutical, Inc. (AskBio)
    • 10.3.15.2 Forge Biologics
    • 10.3.15.3 Takara Bio, Inc.

List of Figures

• Figure 1: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 2: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
• Figure 3: Key Development Analysis from January 2020 to June 2023
• Figure 4: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), % Share, 2022 and 2033
• Figure 5: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), % Share, 2022 and 2033
• Figure 6: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), % Share, 2022 and 2033
• Figure 7: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), % Share, 2022 and 2033
• Figure 8: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Region), Market Snapshot
• Figure 9: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV Segmentation
• Figure 10: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Research Methodology
• Figure 11: Primary Research Methodology
• Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 13: Top-Down Approach (Segment-Wise Analysis)
• Figure 14: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Realistic Scenario), $Million, 2022-2033
• Figure 15: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Optimistic Scenario), $Million, 2022-2033
• Figure 16: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Pessimistic Scenario), $Million, 2022-2033
• Figure 17: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 18: Major Impact
• Figure 19: Minor Impact
• Figure 20: Pros and Cons of Upstream Processing
• Figure 21: Pros and Cons of Downstream Processing
• Figure 22: Addressing Substantial Challenges in AAV Manufacturing
• Figure 23: Process of Manufacturing Pharmaceuticals
• Figure 24: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Market Dynamics
• Figure 25: Clinical Trials in Viral-Vector-Based Gene Therapy from January 2020-May 2023 (by Phase)
• Figure 26: Number of Cell and Gene Therapy Developers (by Region)
• Figure 27: Cost of Goods (CoGs) in Manufacturing Scale
• Figure 28: Cost of Upstream Processing and Downstream Processing in Manufacturing Scales
• Figure 29: Share of Key Developments, January 2020-June 2023
• Figure 30: Number of Product Launches (by Company), January 2020-May 2023
• Figure 31: Market Share Analysis of the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Company), 2022
• Figure 32: Growth-Share Analysis for Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), 2023-2033
• Figure 33: Supply Chain Analysis
• Figure 34: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
• Figure 35: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), % Share, 2022 and 2033
• Figure 36: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase I), $Million, 2022-2033
• Figure 37: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase II), $Million, 2022-2033
• Figure 38: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase III), $Million, 2022-2033
• Figure 39: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Commercial Phase), $Million, 2022-2033
• Figure 40: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
• Figure 41: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), % Share, 2022 and 2033
• Figure 42: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Upstream Processing), $Million, 2022-2033
• Figure 43: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Downstream Processing), $Million, 2022-2033
• Figure 44: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Formulation and Fill and Finish), $Million, 2022-2033
• Figure 45: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
• Figure 46: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), % Share, 2022 and 2033
• Figure 47: Some Examples of AAV Vectors Employed in Oncology
• Figure 48: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Oncology), $Million, 2022-2033
• Figure 49: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Ophthalmology), $Million, 2022-2033
• Figure 50: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Infectious Disease), $Million, 2022-2033
• Figure 51: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Metabolic Disorder), $Million, 2022-2033
• Figure 52: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Neurological Disorder), $Million, 2022-2033
• Figure 53: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Other), $Million, 2022-2033
• Figure 54: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
• Figure 55: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), % Share, 2022 and 2033
• Figure 56: Adherent Platform
• Figure 57: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Adherent Culture), $Million, 2022-2033
• Figure 58: Suspension Platform
• Figure 59: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Suspension Culture), $Million, 2022-2033
• Figure 60: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Region)
• Figure 61: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 62: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
• Figure 63: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 64: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 65: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 66: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 67: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 68: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 69: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 70: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 71: U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 72: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 73: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 74: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 75: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 76: Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 77: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 78: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
• Figure 79: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 80: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 81: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 82: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 83: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 84: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 85: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 86: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 87: U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 88: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 89: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 90: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 91: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 92: Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 93: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 94: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 95: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 96: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 97: France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 98: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 99: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 100: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 101: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 102: Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 103: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 104: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 105: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 106: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 107: Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 108: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 109: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 110: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 111: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 112: Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 113: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 114: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
• Figure 115: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 116: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 117: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 118: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 119: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 120: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 121: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 122: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 123: China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 124: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 125: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 126: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 127: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 128: Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 129: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 130: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 131: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 132: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 133: India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 134: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 135: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 136: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 137: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 138: Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 139: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 140: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 141: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 142: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 143: South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 144: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 145: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 146: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 147: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 148: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 149: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 150: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
• Figure 151: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 152: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 153: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 154: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 155: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 156: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 157: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 158: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 159: Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 160: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 161: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 162: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 163: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 164: Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 165: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 166: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 167: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 168: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 169: Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 170: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 171: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
• Figure 172: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 173: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 174: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 175: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 176: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 177: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 178: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 179: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 180: K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 181: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 182: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 183: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 184: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 185: U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 186: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 187: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 188: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 189: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 190: Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 191: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 192: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 193: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 194: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 195: Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 196: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 197: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 198: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 199: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 200: South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 201: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
• Figure 202: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
• Figure 203: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
• Figure 204: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
• Figure 205: Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
• Figure 206: Total Number of Companies Profiled
• Figure 207: AGC Biologic s.: Service Portfolio
• Figure 208: AGC Biologics.: Overall Financials, $Million, 2020-2022
• Figure 209: AGC Biologics.: Revenue (by Segment), $Million, 2020-2022
• Figure 210: Charles River Laboratories International, Inc.: Service Portfolio
• Figure 211: Charles River Laboratories International, Inc.: Overall Financials, $Million, 2020-2022
• Figure 212: Charles River Laboratories International, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 213: Charles River Laboratories International, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 214: Catalent, Inc.: Service Portfolio
• Figure 215: Catalent, Inc.: Overall Financials, $Million, 2020-2022
• Figure 216: Catalent, Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 217: Catalent, Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 218: Creative Biogene: Service Portfolio
• Figure 219: Danaher. (Cytiva): Service Portfolio
• Figure 220: Danaher. (Cytiva): Overall Financials, $Million, 2020-2022
• Figure 221: Danaher. (Cytiva): Revenue (by Segment), $Million, 2020-2022
• Figure 222: Danaher. (Cytiva): Revenue (by Region), $Million, 2020-2022
• Figure 223: Danaher. (Cytiva): R&D Expenditure, $Million, 2020-2022
• Figure 224: FUJIFILM Diosynth Biotechnologies: Service Portfolio
• Figure 225: Genscript Biotech Corporation (GenScript ProBio): Service Portfolio
• Figure 226: Genscript Biotech Corporation (GenScript ProBio): Overall Financials, $Million, 2020-2022
• Figure 227: Genscript Biotech Corporation (GenScript ProBio): Revenue (by Segment), $Million, 2020-2022
• Figure 228: Genscript Biotech Corporation (GenScript ProBio): Revenue (by Region), $Million, 2020-2022
• Figure 229: Genscript Biotech Corporation (GenScript ProBio): R&D Expenditure, $Million, 2020-2022
• Figure 230: Lonza.: Service Portfolio
• Figure 231: Lonza.: Overall Financials, $Million, 2020-2022
• Figure 232: Lonza.: Revenue (by Segment), $Million, 2021 and 2022
• Figure 233: Merck KGaA: Service Portfolio
• Figure 234: Merck KGaA: Overall Financials, $Million, 2020-2022
• Figure 235: Merck KGaA: Revenue (by Segment), $Million, 2020-2022
• Figure 236: Merck KGaA: Revenue (by Region), $Million, 2020-2022
• Figure 237: Porton Advanced Solution Ltd.: Service Portfolio
• Figure 238: PackGene Biotech: Service Portfolio
• Figure 239: Oxford Biomedica plc: Service Portfolio
• Figure 240: Oxford Biomedica plc: Overall Financials, $Million, 2020-2022
• Figure 241: Oxford Biomedica plc: Revenue (by Segment), $Million, 2020-2022
• Figure 242: Oxford Biomedica plc: Revenue (by Region), $Million, 2020-2022
• Figure 243: Thermo Fisher Scientific Inc. (Patheon Pharma Services): Service Portfolio
• Figure 244: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
• Figure 245: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
• Figure 246: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
• Figure 247: Thermo Fisher Scientific Inc.: R&D Expenditure, 2020-2022
• Figure 248: WuXi AppTec: Service Portfolio
• Figure 249: WuXi AppTec: Overall Financials, $Million, 2020-2022
• Figure 250: WuXi AppTec: Revenue (by Segment), $Million, 2021 and 2022

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Impact Analysis, Market Drivers and Restraints
• Table 3: Pipeline Analysis of Manufactures in AAV-Based Gene Therapy
• Table 4: Investment in Viral-Vector Manufacturing
• Table 5: Limitations Associated with Analytical Method for AAV Quality Control (QC)
• Table 6: Collaboration and Partnerships
• Table 7: North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
• Table 8: Pipeline AAV-Based Gene Therapies in the U.S.
• Table 9: Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
• Table 10: Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
• Table 11: Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
• Table 12: Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis